NUDT15 (mutated) (N = 13) n (%)/ Median (IQR) | Wild Genotype (N = 102) n (%)/ Median (IQR) | p value | |
---|---|---|---|
Hemoglobin (g/dL) at end of follow up | 12 (2.8) | 11.05 (3.4) | 0.289 |
Total leucocyte count (× 106/L) at end of follow up | 3600 (1700) | 5700 (3575) | 0.006 |
Platelet count (× 106/L) at end of follow up | 214,000 (109,000) | 254,000 (132,500) | 0.289 |
Duration of thiopurine use (months) | 11 (9) | 8 (15.25) | 0.168 |
Max tolerated azathioprine equivalent dose (mg/d) | 50 (50) | 100 (25) | 0.253 |
Leukopenia | 7 (53.8%) | 25 (24.5%) | 0.026 |
Idiosyncratic reaction | 0 | 6 (5.9%) | 1.000 |
Treatment interruption | 7 (53.8%) | 29 (28.4%) | 0.063 |